Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q8N6N7
UPID:
ACBD7_HUMAN
Alternative names:
-
Alternative UPACC:
Q8N6N7; A6NCI2; B3KTG8
Background:
Acyl-CoA-binding domain-containing protein 7 plays a crucial role in cellular metabolism by binding medium- and long-chain acyl-CoA esters. This interaction is pivotal for the regulation of intracellular lipid metabolism and energy production.
Therapeutic significance:
Understanding the role of Acyl-CoA-binding domain-containing protein 7 could open doors to potential therapeutic strategies. Its involvement in lipid metabolism suggests a possible link to metabolic disorders, offering a new avenue for research and drug development.